REACH - non-regulatory announcement
9 April 2024
Tern Plc
("Tern"
or the "Company")
Talking Medicines reports
record revenue bookings and strategic partnerships in Q1
2024
Tern Plc (AIM:TERN),
the investment company specialising in supporting
high growth, early-stage, disruptive Internet of Things ("IoT")
technology businesses, is pleased to
note that Talking Medicines Limited
("Talking Medicines"), a company in which Tern currently holds
23.8% of the equity, has announced an update on its Q1 2024
performance, extracts of which are set out below.
Extracts from the Talking Medicines
announcement:
"Talking Medicines, a pioneering
leader in healthcare intelligence leveraging advanced data science
and artificial intelligence, is pleased to announce a strong start
to 2024, marked by record revenue bookings and significant
advancements in its innovative platform, Talking Medicines
Drug-GPT.
In the first quarter of 2024,
Talking Medicines achieved significant success with its Talking
Medicines Drug-GPT platform, which aims to revolutionise access to
intelligence on pharmaceutical medicine brands and disease areas.
This innovative technology has garnered substantial interest
from leading global healthcare advertising agencies, who recognise
its potential to transform strategies for pharmaceutical
clients.
Among Talking Medicines' clients are
some of the world's most prominent healthcare advertising agency
networks, reaffirming the platform's efficacy in providing key
insights derived from aggregated patient and healthcare
professional conversations. By tapping into previously unseen
data, Talking Medicines empowers its clients to drive better
strategies and make informed decisions in relation to the
pharmaceutical landscape.
Furthermore, Talking Medicines has
forged strategic partnerships with both open and closed data
communities, solidifying its commitment to expanding access to
crucial insights. Notable among these partnerships is the
collaboration with data aggregator Socialgist, which enables
Talking Medicines to tap into millions of public conversational
sites, enriching the Talking Medicines Drug-GPT platform with a
wealth of diverse data sources.
Speaking on these achievements, Jo
Halliday CEO expressed excitement about the company's trajectory
and the transformative impact of Talking Medicines Drug-GPT on the
healthcare industry: "We are thrilled by the broad response to
Talking Medicines Drug-GPT and our strategic partnerships. This
success underscores our dedication to empowering healthcare
stakeholders with actionable insights derived from advanced data
science and artificial intelligence."
Looking ahead, Talking Medicines
remains committed to driving innovation and fostering
collaborations that enhance healthcare decision-making through
intelligence globally."
About Talking Medicines
Talking Medicines is a leading
provider of healthcare intelligence, leveraging advanced data
science and artificial intelligence to transform pharmaceutical
brand strategies. The company's innovative platform, Talking
Medicines Drug-GPT, revolutionises access to intelligence on
pharmaceutical medicine brands and disease areas, empowering
healthcare stakeholders with actionable insights derived from
aggregated patient and healthcare professional conversations. For
more information, visit: www.talkingmedicines.com
Enquiries
|
Tern Plc
Ian Richie
Chairman
|
via IFC Advisory
|
|
Allenby Capital Limited
(Nominated Adviser and
Broker)
Alex Brearley / Dan Dearden-Williams
(Corporate Finance)
Kelly Gardiner / Guy McDougall
(Sales and Corporate Broking)
|
Tel: 0203 328 5656
|
|
IFC
Advisory
(Financial PR and IR)
Tim Metcalfe
Graham Herring
Florence Chandler
|
Tel: 0203 934 6630
|
About Reach announcements
This is a Reach announcement. Reach
is an investor communication service aimed at assisting listed and
unlisted (including AIM quoted) companies to distribute media only
/ non-regulatory news releases into the public domain. Information
required to be notified under the AIM Rules for Companies, Market
Abuse Regulation or other regulation would be disseminated as an
RNS regulatory announcement and not on Reach.
